Try our Advanced Search for more refined results
April 27, 2010
Celgene Corporation v. Cyclacel Pharmaceuticals Inc.
Case Number:
1:10-cv-00348
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
April 04, 2013
Celgene's $5.5M Patent Buy Ends Cancer-Therapy IP Row
Biopharmaceutical company Cyclacel Pharmaceuticals Inc. has agreed to sell four patents to rival Celgene Corp. for $5.5 million, ending federal litigation in Delaware over the validity of the patents and whether they were infringed by Celgene's cancer treatment Istodax, Cyclacel announced Thursday.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login